financetom
Business
financetom
/
Business
/
Loar Set to Grow Beyond Projections Despite Macro Air Travel Challenges, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Loar Set to Grow Beyond Projections Despite Macro Air Travel Challenges, RBC Says
Apr 1, 2025 9:00 AM

11:43 AM EDT, 04/01/2025 (MT Newswires) -- Loar Holdings ( LOAR ) raised its 2025 guidance when it reported Q4 results, however, there is still potential for further growth beyond the current projections, RBC Capital Markets said in a note Monday.

Analysts, including Ken Herbert, said management has raised its expectations for revenue, adjusted earnings before interest, taxes, depreciation, and amortization, and adjusted earnings per share in 2025. The analysts believe this increase is due to "better" demand in the aftermarket sector, positive tailwinds in defense, and improved productivity.

"Although the macro backdrop for air travel has softened," RBC analysts said they believe the company "will continue to benefit from multiple tailwinds."

The analysts said their positive outlook on Loar ( LOAR ) is based on several key points. First, the aerospace company generates 85% of its 2024 revenue from proprietary products, which allows the company to "benefit from strong pricing tailwinds." Second, it achieved 36.3% adjusted EBITDA margins in 2024, with a "high" visibility for continued margin growth. They added that Loar's ( LOAR ) "disciplined" approach to mergers and acquisitions will remain a key factor for stock growth. The company also generates about 70% of its EBITDA from the aftermarket, according to the note.

The analysts said that Loar's ( LOAR ) upcoming acquisition of LMB will boost its presence in the expanding European defense market, and any additional mergers and acquisitions would likely drive the stock higher.

RBC reiterated an outperform rating on the stock with a $92 price target.

Price: 69.73, Change: -0.92, Percent Change: -1.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved